Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer

Por Parekh, Parag, Kamble, Sanchit, Zhao, Nianxi, Zeng, Zihua, Portier, Bryce P., Zu, Youli
Publicado em 2013

MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuz...

Por Calhoun, Benjamin C., Portier, Bryce, Wang, Zhen, Minca, Eugen C., Budd, G. Thomas, Lanigan, Christopher, Tubbs, Raymond R., Morrison, Larry E.
Publicado no BMC Cancer (2016)

HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma

Por Portier, Bryce P, Minca, Eugen C, Wang, Zhen, Lanigan, Christopher, Gruver, Aaron M, Downs-Kelly, Erinn, Budd, G Thomas, Tubbs, Raymond R
Publicado em 2013

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells

Por Fiskus, Warren, Sharma, Sunil, Shah, Bhavin, Portier, Bryce P., Devaraj, Santhana G. T., Liu, Ka, Iyer, Swaminathan P., Bearss, David, Bhalla, Kapil N.
Publicado no Leukemia (2014)

BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD

Por Fiskus, Warren, Sharma, Sunil, Qi, Jun, Shah, Bhavin, Devaraj, Santhana G. T., Leveque, Christopher, Portier, Bryce P., Iyer, Swaminathan, Bradner, James E., Bhalla, Kapil N.
Publicado em 2014

Proficiency testing of standardized samples shows very high inter-laboratory agreement for clinical next generation sequencing-based oncology assays

Por Merker, Jason D., Devereaux, Kelly, Iafrate, A. John, Kamel-Reid, Suzanne, Kim, Annette S., Moncur, Joel T., Montgomery, Stephen B, Nagarajan, Rakesh, Portier, Bryce P., Routbort, Mark J., Smail, Craig, Surrey, Lea F., Vasalos, Patricia, Lazar, Alexander J., Lindeman, Neal I.
Publicado no Arch Pathol Lab Med (2018)